Achillion begins patient dosing in Phase 2b study of HCV candidate
Achillion Pharmaceuticals (ACHN) announced that patient dosing in a global Phase 2b open-label OMEGA-1 study of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, has been initiated by Janssen Research & Development, part of the Janssen Pharmaceutical Companies of Johnson & Johnson - Janssen -, in treatment-naive and treatment-experienced patients with chronic hepatitis C virus infection without cirrhosis. The objectives of OMEGA-1 are to investigate the efficacy, safety and pharmacokinetics of JNJ-4178, simeprevir and AL-335 in treatment-naive and treatment-experienced non-cirrhotic patients with chronic hepatitis C virus genotype 1, 2, 4, 5, and 6 infection. Patients in the study will receive the triple combination once daily for either 6 or 8 weeks. The primary efficacy endpoint will be the percentage of patients with a sustained virological response 12 weeks after the end of treatment.